Whoop has moved beyond wearables, with the maker of the screenless Whoop 5.0 fitness tracker now offering blood testing outside its subscription model. The company announced the shift on Tuesday, introducing an initiative called Advanced Labs that lets users buy tests on an a la carte basis rather than committing to a recurring plan.
For the programme, Whoop is working with medical lab testing company Quest Diagnostics to measure more than 122 biomarkers across heart, metabolic, performance and hormonal health, among other areas. Panels can measure glucose, sodium, calcium and more.
How Whoop’s blood tests work
Prices range from roughly £55 to £235, depending on the blood work panel selected. After choosing a panel, users can schedule a test at a Quest location through the Whoop app, and a doctor will order it. There is a window of up to 12 months to schedule the test after the purchase date, and HSA or FSA funds may be eligible, though users are advised to confirm with their plan provider first.
These fees are separate from a Whoop membership, which ranges from about £156 to £282. Once results are in, a doctor reviews them and provides an action plan, which is available in the Whoop app. Users also receive personalised AI insights that add context to the results and support building the action plan. No wearable is required for these insights.
Availability varies by location. Advanced Labs is currently unavailable in Hawaii, Wyoming, South Dakota and North Dakota. In New York, New Jersey and Rhode Island, state law requires an additional fee for each blood panel, which varies by panel and is collected at the lab appointment upon check-in.
A multicancer early detection test
Alongside the Advanced Labs expansion, Whoop has added the Galleri multicancer early detection test to its offerings. Created by the Grail clinical laboratory, Galleri costs about £630 and is designed to detect cancer signals associated with more than 50 cancer types. After blood is drawn at a Quest location, the test is performed at Grail’s North Carolina lab.
Galleri is not a diagnosis, has not been FDA-approved, does not detect all cancers and should not be used as a replacement for routine cancer screenings recommended by a doctor. It is specifically recommended for adults with an elevated cancer risk, such as those aged 50 or older. It is not recommended for pregnant people, individuals aged 21 or younger or those actively being treated for cancer.
If a cancer signal is detected, follow-up testing is required for more information. A doctor will reach out about next steps, and users can also contact a Grail patient advocate.
